No Free Launch: At-Risk Entry by Generic Drug Firms
收藏NBER2021-08-01 更新2025-01-04 收录
下载链接：
https://www.nber.org/papers/w29131
下载链接
链接失效反馈官方服务：
资源简介：
After receiving FDA approval, a generic drug manufacturer can launch at risk before conclusion of any patent infringement litigation, but it risks paying damages if it loses. The generic can eliminate the risk by waiting to launch until the appeals process is complete but waiting has downsides too.
提供机构：
美国国家经济研究局
创建时间：
2021-08-01
